Low Dose Radiotherapy (LDRT) Can Be an Option For Curing COVID-19?
Keywords:: Radiotherapy, COVID-19, Low dose, Pneumonia, Radiation
In December 2019, the epidemic of Coronavirus Disease 2019 (COVID-19) broke out in Wuhan in China.
Symptoms of COVID-19 are non-definite and mild symptoms include: fever, cough. However, elderly
and populations with comorbidities such as diabetes, hypertension are more likely to be at risk of severe
pulmonary infection and death. Many therapies have been proposed and assed for treating (COVID-19). In
April 2020, two papers appeared that suggested clinical trials of low dose radiotherapy (LDRT) for COVID19 pneumonia. Following that, some researchers carried out some studies, and they modify the amount
of doses and fractionation. Regarding the aging, some study using a sensitive age that ranged from 18 to
50 years, are more likely to have stochastic effects that cannot analyzed directly as it needs more time to
experience these effects. In this review, we analysis the possibility of a low dose radiotherapy that can have
in treating COVID-19 pneumonia, by using almost all accessed publications that performed on a low dose
radiotherapy (LDRT) for curing bacteria or virus as well as studies that focus on using LDRT for antiinflammatory. We show that LDRT can perform the mitigation and the repair response of the immune system
to provide a potential therapy of COVID-19. A single dose of low-dose radiotherapy can be effective in
both cost and time and could potentially relieve symptoms of respiratory rapidly. However, such treatment
would not be without obstacle and it can be difficult since it is necessary to recognize those few patients
who are more benefit from radiation treatment and identifying short and long-term impacts. clinical stage of
disease should be known. Additionally, it is not acceptable to report that LDRT would be superior to any type
treatment that are currently under taking, until results from clinical trial will be released.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions